Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
This post hoc analysis of the DURATION-1 trial evaluated the effects of exenatide administered once weekly (ExQW) or twice daily (ExBID) over 30 weeks on cardiovascular risk markers in 211 patients with type 2 diabetes. Both regimens led to significant reductions in triglycerides, very low-density lipoprotein cholesterol (VLDL-C), and high-sensitivity
June 26, 2025
No Comments